Meta-Analysis Reveals Cognitive Behavioral Therapy Ineffective for MS-Related Fatigue
Individualizing Disease-Modifying Therapy Selection in Newly Diagnosed MS: Gabrielle Macaron, MD
Real-World Safety of Cladribine Matches Clinical Trial Development
OPTIMUM Phase 3 Extension Further Highlights Sustained Efficacy, Safety of Ponesimod